Structures of TGF-β Receptor Complexes: Implications for Function and Therapeutic Intervention Using Ligand Traps
Abstract
TGF-β isoforms (TGF-β1, -β2, and -β3) are secreted signaling ligands that stimulate the expression of protein components of the extracellular matrix, regulate the growth and differentiation of epithelial cells, modulate immune cell function, and play roles in the development of several essential organs, including the heart and lungs. The importance of the TGF-βs is underscored by their conservation among vertebrates and by their demonstrated roles in a variety of human diseases, including tissue fibrosis and cancer. The objective of this review is to highlight recent progress in characterizing the structures of the three TGF-β isoforms in complex with their receptors, and to compare these with one another as well as with other members of the superfamily. Although the structural information and accompanying biophysical studies emphasize the shared ancestry of TGF-βs, they also provide insight as to how the TGF-βs diverged from other members of the superfamily and one another to fulfill distinct roles in vivo. The similarities and differences by which the isoforms bind their receptors present unique opportunities for designing pan-isoform and isoform-specific ligand traps and progress toward developing these is described.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Fc-TβRII trap was the basis for the development of a bi-specific trap that combines TGF-β binding by the TβRII ectodomains with a human PD-L1-blocking IgG1.
“The Fc-TβRII trap was also the basis for the development of a bi-specific trap that combines TGF-β binding by the TβRII ectodomains with a human PD-L1-blocking IgG1308,309,312.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [309]
Bifunctional fusion proteins that bind and block both TGF-β and CTLA-4 or PD-L1 have been generated, biochemically linking checkpoint inhibition with TGF-β blockade.
“Bifunctional fusion proteins that bind and block both TGF-β and CTLA-4 or PD-L1 have been generated, thus biochemically linking immune checkpoint inhibition with blocking TGF-β signaling308,309,365.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [309]
Anti-CTLA-4-TβRII had superior anti-tumor activity in a breast cancer mouse model compared with anti-TGF-β or a combination of anti-CTLA-4 and anti-TGF-β.
“Anti-CTLA-4-TβRII had superior anti-tumor activity in a breast cancer mouse model, compared with anti-TGF-β or a combination of anti-CTLA-4 and anti-TGF-β309.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [309]
Cited by
Sorted by citations
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works
TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 300 · see citing works
“These comprise dimers of TβRII ectodomains (Fc-stabilized) that are designed to sequester TGF-β1 and TGF-β3, but not TGF-β2, and thus prevent them binding to receptors [174,175].”
BackgroundPoniatowski, Ł. A., Wojdasiewicz, P., Gasik, R., & Szukiewicz, D. (2015) · Mediators of Inflammation · doi:10.1155/2015/137823 · Cited by 282 · see citing works
Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue
Petrus, P., Mejhert, N., Corrales, P., Lecoutre, S., Li, Q., Maldonado, E., Kulyté, A., López, Y., Campbell, M., Acosta, J. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.069 · Cited by 123 · see citing works
Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy
Villalba-Esparza, M., Evans, S. R., Vidal‐Vanaclocha, F., & Calvo, A. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2633-9 · Cited by 103 · see citing works
“The functional role of the three isoforms is similar as shown by in vitro assays, suggesting functional redundancy (Hinck and O’Connor-McCourt 2011).”
BackgroundLiu, B., Zhu, X., Kong, L., Wang, M., Spanoudis, C. M., Chaturvedi, P., George, V., Jiao, J., You, L., Egan, J. O., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.001 · Cited by 45 · see citing works
Flanders, K. C., Yang, Y.-A., Herrmann, M., Chen, J., Mendoza, N., Mirza, A. M., & Wakefield, L. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9416 · Cited by 39 · see citing works
“Mammals express 3 highly conserved TGF-β isoforms, TGF-β1, TGF-β2, and TGF-β3, which have 70-80% identity in the amino acid sequences of their mature active domains [5].”
Production, Isolation, and Structural Analysis of Ligands and Receptors of the TGF-β Superfamily
Huang, T., & Hinck, A. P. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2966-5_4 · Cited by 35 · see citing works
“Structural studies of signaling proteins and signaling receptors of the TGF-β superfamily have shown that the TGF-βs, evolutionary latecomers to the superfamily, diverged from the BMPs and GDFs, the ancestral signaling proteins of the superfamily, to bind and assemble their type I and type II receptors in a distinct m…”
BackgroundSelf-citationA Short Peptide That Mimics the Binding Domain of TGF-β1 Presents Potent Anti-Inflammatory Activity
Vaz, E. R., Fujimura, P. T., Araujo, G. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136116 · Cited by 21 · see citing works
“These two residues are responsible for over 30% of total binding energy, which results in a high-affinity interaction between isoforms of this molecule and TβRII receptor [41].”
BackgroundExpression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma
Liu, Y., Liu, M., chuanzong, D., et al. (2012) · Tumor Biology · doi:10.1007/s13277-012-0398-z · Cited by 17 · see citing works
Jaschinski, F., Korhonen, H., & Janicot, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_9 · Cited by 14 · see citing works
Betaglycan knock‐down causes embryonic angiogenesis defects in zebrafish
Kamaid, A., Molina‐Villa, T., Mendoza, V., et al. (2015) · genesis · doi:10.1002/dvg.22876 · Cited by 13 · see citing works
“Our sequence analysis indicated that TGFBR3L transcript encodes a polypeptide 861 residues long, a size that resembles other BGs ( 850 aa), but not the EGs ( 650 aa).”
BackgroundInfluentialResidues of Alpha Helix H3 Determine Distinctive Features of Transforming Growth Factor β3
Nayeem, S. M., Oteri, F., Baaden, M., & Deep, S. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b01867 · Cited by 11 · see citing works
Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily
Kumar, R., Grinberg, A. V., Li, H., Kuo, T., Sako, D., Krishnan, L., Liharska, K., Li, J., Grenha, R., Maguire, M. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97203-9 · Cited by 11 · see citing works
Roles of TGF-β in cancer hallmarks and emerging onco-therapeutic design
Dai, X., Hua, D., & Lu, X. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.37 · Cited by 10 · see citing works
pH modulates the TGF‐β ligands binding to the receptors: a computational analysis
Nayeem, S. M., & Deep, S. (2014) · Journal of Molecular Recognition · doi:10.1002/jmr.2368 · Cited by 5 · see citing works
“The three TGF-βs are structurally similar with TGF-β2 and TGF-β3 sharing 92% of sequence similarity, TGF-β1 and TGF-β3 sharing 87% sequence similarity, and TGF-β1 and TGF-β2 sharing 86% sequence similarity (Hinck and O’Connor-McCourt, 2011).”
BackgroundTGF-β in hematologic malignancies: molecular functions and clinical applications
Li, R., Fang, W., & Ml, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1728730 · Cited by 3 · see citing works
Corneal thinning and cornea guttata in patients with mutations in TGFB2
Eghrari, A. O., Rasooly, M. M., Fliotsos, M. J., et al. (2020) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2020.03.007 · Cited by 3 · see citing works
Investigational serine/threonine kinase inhibitors against prostate cancer metastases
Festuccia, C. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1266337 · Cited by 3 · see citing works
“PI3K/AKT/mTOR pathway is an established oncogenic driver in humans and preclinical and clinical studies demonstrate univocally that inhibitors of this pathway are useful in overcoming resistance to treatments and improving standard therapies in CRPC as well as could modify EMT and bone metastases [20,33].”
BackgroundYAP and TAZ are Mechanoregulators of TGF-β-Smad Signalling and Fibrogenesis
Szeto, S. G. (2015) · TSpace (University of Toronto)
- Authors
- P. Hinck, A., & D. O'Connor-McCourt, M.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-12-01
- Volume
- 12
- Issue
- 12
- Pages
- 2081-2098
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2320026459
- Cited by
- 21
- References
- 0
- Citations by year
- 2026: 1 · 2022: 1 · 2021: 3 · 2020: 2 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 6 · 2014: 1 · 2012: 1
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- NPARC (submittedVersion)
- Funders
- Amgen
- National Institute of General Medical Sciences (GM 58670, R01GM058670)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Keywords
- TGF-beta isoforms, TGF-beta receptor, receptor complex, protein structure, ligand trap, TGF-beta superfamily, TGF-β1, TGF-beta2, TGF-beta3, fibrosis, cancer, drug design
- MeSH terms
- Animals, Humans, Ligands, Transforming Growth Factor beta, Receptors, Transforming Growth Factor beta, Protein Isoforms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
